Nevertheless, despite the results presented suggesting favorable outcomes of de-escalated therapies in stage I HER2-positive breast cancer, no trials have confirmed that tumors smaller than 1 cm benefit from chemotherapy with trastuzumab compared to no systemic treatment. This evidence concerns the gene ERBB2 and breast carcinoma.